About the Cancer Evolvability Program

Evolution of tumors and infectious diseases occurs by variation and selection. Variation creates the ability to evolve (evolvability). Whereas conventional therapies kill cells or stop them from growing (are anti-proliferative), proposed novel interventions that would inhibit the ability to evolve promise new and fundamentally different ways to inhibit oncogenesis and thwart resistance. Two basic routes generate variation: (1) intrinsic genomic and phenotypic instability (mutation, genome rearrangement, recombination, epigenetic and stochastic protein and RNA variation); and (2) extrinsic-introduction of foreign genes, proteins, RNAs and other molecules and genetic programs by infectious agents (viruses, microbes, microbiome). This program encompasses both routes to generating the diversity that propel evolution of cancers and their resistance to therapies.

Members

David Bates, Ph.D. 
Alison Bertuch, M.D., Ph.D.
Robert Britton, Ph.D.
Janet S. Butel, Ph.D.
Elizabeth Chiao, M.D., M.B.A.
Gretchen Diehl, Ph.D.
Mary Estes, Ph.D.
Ido Golding, Ph.D.
Philip Hastings, Ph.D.
Christophe Herman, Ph.D.
Joseph Hyser, Ph.D.
Grzegorz Ira, Ph.D.
Ron Javier, Ph.D.
Jason Kimata, Ph.D.
Erez Lieberman Aiden, Ph.D.
Paul Ling, Ph.D.
Dongfang Liu, Ph.D.
Richard Lloyd, Ph.D.
James Lupski, M.D., Ph.D.
Susan Marriott, Ph.D.
Kyle M. Miller, Ph.D. (U Texas, Austin) 
Martha Mims, M.D.
Bhagavatula Moorthy, Ph.D. 
Mary Paul, M.D.
Joseph Petrosino, Ph.D.
Venkatar Prasad, Ph.D.
Andrew Rice, Ph.D. 
Susan M. Rosenberg, Ph.D.
Shelley Sazer, Ph.D. 
Michael Scheurer, Ph.D. 
Betty Slagle, Ph.D. 
Zhou Songyang, Ph.D. 
Pawel Stankiewicz, M.D. 
James Versalovic, M.D., Ph.D. 
Meng Wang, Ph.D.
Pumin Zhang, Ph.D. 
Chenghang (Chuck) Zong, Ph.D.